Why BAT's 5% Yield Still Isn't Cheap Enough After the H1 Re-Rating

The 52.1% Re-Rating Changed the Valuation Math

After a 52.1% one-year total return, BAT no longer looks cheap simply because the yield is still attractive. At 4,570p, roughly 13x earnings with a 5%+ dividend yield, the stock offers familiar income and an old-tobacco multiple, but also a recovery narrative that already feels familiar to the market. That does not make the business unattractive. It does mean the margin of safety is smaller than it was.

The market reaction to the latest results supports that distinction. The shares fell after the release and are below their May peak even though management still says it is firmly on track to deliver FY guidance. This looks less like a collapse in business prospects and more like a repricing of expectations. Bulls can still point to confident Full-Year 26 guidance, continued U.S. delivery, and momentum in New Categories, especially Modern Oral. But those are execution strengths, not proof that the current valuation is generous.

H1 Improvement Was Real, but Still Narrowly Driven

Growth is real, but concentrated in the U.S. and Modern Oral

BAT did deliver a credible operating improvement. Half-year revenue rose 1.4%, or 2.9% at constant FX, New Categories revenue increased by 18.0%, and U.S. Modern Oral grew 220%. Management also highlighted a return to double-digit growth in U.S. Vapour. Those results suggest transformation is continuing, not stalling.

The limitation is breadth. The same H1 summary says growth was driven mainly by the U.S., where revenue rose 8.5%, and offset in part by a slower than expected recovery in APMEA. That leaves investors paying more for a portfolio whose improvement is still heavily U.S.-led, rather than seeing a fully balanced recovery across regions.

Adjusted figures improved, but reported metrics stayed messy

The adjusted set looked healthier: profit from operations rose 3.5% and adjusted diluted EPS rose 7.9%. The reported set told a tougher story. Reported profit from operations fell 15.8%, reported diluted EPS fell 28.6%, and free cash flow fell 48.8% to $4.0bn. Underlying net debt remained £31.4bn.

That gap matters. Adjusted figures can be useful, but they do not erase the fact that cash generation and balance-sheet relief still look less clean than the growth narrative alone would suggest. A company can grow higher-quality categories and still leave less room for error if charges, timing effects, or investment needs keep pressuring reported cash flow.

Why the Next Few Quarters Matter More Than the Yield

Management is still confident in FY26 guidance, and the second half has plausible catalysts, including the planned rollout of Velo Max and some U.S. Vuse flavours. That supports the case for continued progress.

But after the recent re-rating, those catalysts deserve a more conservative read. They can help support the stock, yet they do not eliminate the risk that growth remains too concentrated, too U.S.-dependent, or too sensitive to regulation and product-specific execution. For the valuation to be clearly justified, the next few quarters need to show broader execution, not just another decent U.S. quarter.

What Would Make BAT Cheap Again

Regulation and legal precedent still cap the multiple

BAT would likely look cheap again in one of two ways: either the market accepts a lower earnings multiple because legal and regulatory noise keeps the old-tobacco label attached to the stock, or execution broadens enough to deserve the current premium. The legal backdrop is not just a background scare. Canada moved from threat to precedent through the C$32.5 billion settlement approved by a Canadian court, and management has warned of significant regulatory and fiscal headwinds in Australia. That helps explain why the sector multiple can stay restrained even when the operating story is improving.

The clearest watchpoints are balance and discipline

The next few quarters matter most for three reasons: - whether growth broadens beyond the U.S. - whether New Category momentum translates into cleaner reported cash flow - whether regulation or settlement-style liabilities widen faster than execution improves

If H2 brings balanced capital allocation, wider regional delivery, and no fresh regulatory shocks, the market may keep rewarding execution. If not, paying roughly 13x earnings for a 5% yield still looks more emotionally comfortable than genuinely cheap. For now, the cleaner stance is to wait for either a cheaper entry multiple or clearer proof that the recovery is becoming broadly based.